ADICON Holdings Limited 艾迪康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9860） 提名委員會的職權範圍 艾迪康控股有限公司（「本公司」）的提名委員會（「提名委員會」）乃根據本公司董事會 （「董事會」）於2023年6月3日通過的決議案成立。下文載列提名委員會的職權範圍 （「職權範圍」）。職權範圍備有英文及繁體中文版本可供查閱。如職權範圍的英文版 本與繁體中文版本有任何歧義，概以英文版本為准。 目的 1. 提名委員會成立之目的，旨在為董事會物色、篩選及推薦合適人選出任本公司 董事、監察評估董事會表現的程序、制定及向董事會建議提名指引，惟須符合 任何適用法律、法規及上市標準。 組成 – 1 – 2. 提名委員會須由董事會不時委任，並須由三名成員（「成員」）組成。提名委員會 的大部分成員須為本公司獨立非執行董事，並須不時符合及維持香港聯合交易 所有限公司證券上市規則（「上市規則」）（經不時修訂）所規定的獨立性規定。 3. 提名委員會應有至少一名不同性別的成員。 4. 提名委員會主席（「主席」）應由董事會主席或本公司獨立非執行董事擔任。 5. 提名委員會秘書（「秘書」）須由本 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 本公告載有涉及風險及不確定因素的前瞻性陳述。除歷史事實陳述以外的所有陳述均為前瞻性陳 述。該等陳述涉及已知及未知的風險、不確定因素及其他因素，當中部分並非本公司所能控制，且 可導致實際業績、表現或成果與前瞻性陳述所明示或暗示者存在重大差異。 閣下不應依賴前瞻性 陳述作為未來事件的預測。本公司概不負責更新或修訂任何前瞻性陳述，無論是否由於新資料、未 來事件或其他因素所致。 ADICON Holdings Limited 艾迪康控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：9860） 截 至2025年6月30日止六個月之 中期業績公告 董事會欣然宣佈本集團截至2025年6月30日止六個月之未經審核綜合中期業績以及 2024年同期之比較數字。 於本公告內，「我們」指本公司，如文義另有所指，則指本集團。本公告內所載的若 干金額及百分比數字已作出約整。任何表格、圖表或其他地方所列總數與金額總和 之間的 ...

格隆汇8月12日丨艾迪康控股(09860.HK)宣布，本公司将于2025年8月22日（星期五）举行董事会会议， 其中议程包括考虑及批准刊发本公司及其附属公司截至2025年6月30日止六个月的未经审核综合中期业 绩公告。 ...

艾迪康控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：9860） 董事會會議召開日期 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 艾迪康控股有限公司（「本公司」）之董事（「董事」）會（「董事會」）謹此宣佈，本公司將 於2025年8月22日（星期五）舉行董事會會議，其中議程包括考慮及批准刊發本公司 及其附屬公司截至2025年6月30日止六個月之未經審核綜合中期業績公告。 ADICON Holdings Limited 主席 楊凌女士 香港，2025年8月12日 於本公告日期，董事會包括執行董事高嵩先生；非執行董事楊凌女士、林繼迅先生、馮軍元女士及 周敏濤先生；以及獨立非執行董事宓子厚先生、葉霖先生及張煒先生。 承董事會命 艾迪康控股有限公司 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 致：香港交易及結算所有限公司 公司名稱: 艾迪康控股有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09860 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF301 ...

Core Viewpoint - The Hang Seng Healthcare Index (HSHCI) has shown positive performance, with significant increases in constituent stocks, indicating a favorable market environment for healthcare investments [3][4]. Group 1: Market Performance - As of July 28, 2025, the HSHCI rose by 0.64%, with notable gains from stocks such as MicroPort Medical (up 9.51%) and Eddy Health Holdings (up 3.93%) [3]. - The Hang Seng Healthcare ETF (513060) opened higher, increasing by 1.22% to a latest price of 0.66 yuan, and has accumulated a 0.92% rise over the past week [3]. - The ETF recorded a turnover of 0.79% during the trading session, with a transaction volume of 61.18 million yuan, and an average daily trading volume of 2.815 billion yuan over the past week, ranking first among comparable funds [3]. Group 2: Policy and Industry Outlook - The national procurement policy is expected to expand from pharmaceuticals to medical devices, potentially leading to performance reversals in high-value consumables and in vitro diagnostics sectors [4]. - The medical device sector is anticipated to benefit from a recovery in procurement activities this year, with expectations of an earnings turning point in the third quarter [4]. Group 3: ETF Performance Metrics - The latest size of the Hang Seng Healthcare ETF is 7.656 billion yuan, placing it in the top third among comparable funds [4]. - The ETF has seen a net value increase of 29.88% over the past two years, with a maximum monthly return of 28.34% since inception [4]. - The ETF's Sharpe ratio for the past year is 2.30, indicating strong risk-adjusted returns [4]. Group 4: Valuation and Tracking Accuracy - The HSHCI's latest price-to-earnings ratio (PE-TTM) is 31.72, which is below 84.29% of the historical data over the past three years, suggesting a low valuation [6]. - The ETF has the highest tracking accuracy among comparable funds, with a tracking error of 0.060% over the past year [6]. - The top ten weighted stocks in the HSHCI account for 60.54% of the index, including companies like BeiGene and WuXi Biologics [6].

Group 1: Stock Movements and Market Reactions - JunDa Co., Ltd. (02865) fell by 12.69% due to weak fundamentals, expected shareholder sell-off, and cash flow concerns [1] - Rongchang Biopharmaceutical (09995) rose by 4.61% after ASCO announced positive data for RC108 combined with vorinostat, enhancing its commercialization prospects [1] - Datang Gold (08299) increased by 7.27% as it partnered with Wuxi to develop AI mining applications, benefiting from gold's safe-haven demand [1] - Kanglong Chemical (03759) gained 4.35% by investing in a biopharmaceutical fund, strengthening its investment ecosystem [1] - Automotive stocks surged following a significant increase in May's new energy vehicle sales, with Li Auto (2015) rising nearly 6% and Great Wall Motors (2333) up over 3% [1] - Gold stocks led the market as COMEX gold prices returned to $3,400, with Goldman Sachs predicting $4,200, driven by geopolitical tensions [1] Group 2: Company-Specific Developments - Changfei Optical Fiber (06869) rose by 8.34% as its Wuhan base began mass production of 6-inch silicon carbide wafers, achieving a 97% yield rate [2] - China Shipbuilding Defense (00317) increased by 7.58% after securing the highest global new orders from January to April, with Q1 net profit up 1,099% [2] - Hengrui Medicine (00013) rose by 5.09% as SACHI III phase data met expectations, opening up market space for MET amplification lung cancer treatment [2] - Lepu Medical Technology (02157) gained 5.76% following positive ASCO data for its ADC drug MRG003, boosting approval expectations for nasopharyngeal carcinoma [2] - Aidi Kang Holdings (09860) increased by 5.2% after acquiring Suzhou Yuande Youqin to enhance blood disease diagnostics [2] - NetDragon (00777) rose by 5.82% due to its collaboration with Thailand on an AI education platform, attracting investor interest [2] Group 3: Notable Market Trends - China Everbright Holdings (00165) surged over 21% following the enactment of Hong Kong's stablecoin regulations, with Circle's IPO expectations boosting related equity valuations [3] - iFlytek Medical (02506) rose by 6.62% as its medical AI model demonstrated superior accuracy, supported by favorable policies [3] - MicroPort NeuroTech (02172) increased by 9.59% as it initiated clinical research on brain-machine interfaces, benefiting from policy incentives [3] - Longpan Technology (02465) rose by 14.9% after its subsidiary signed a $7.1 billion contract with Yiwei Lithium Energy for lithium iron phosphate [4] - Hansoh Pharmaceutical (03692) gained 3.85% after reaching a global licensing agreement with Regeneron, receiving an $80 million upfront payment [4] Group 4: U.S. Market Highlights - Steel and aluminum stocks surged over 10%-28% as Trump proposed increasing steel tariffs to 50%, benefiting domestic companies [5] - Blueprint Medicines (BPMC.US) rose by 26% following Sanofi's $9.1 billion acquisition, enhancing its rare disease pipeline [5] - BioNTech (BNTX.US) increased by 18% due to a collaboration with Bristol-Myers Squibb, securing a $1.5 billion upfront payment [5] - Applied Digital (APLD.US) surged by 48.46% after signing a $7 billion AI data center lease, validating its business model [5] - Tempus AI (TEM.US) rose by 15% as it launched an AI medical innovation plan, attracting investor interest [7]

大摩表示，以艾迪康控股为例，在其自主研发的实验室信息系统(LIS)和近期突破式AI技术整合的帮助 下，2024年其试剂和履约成本分别降低了10%和6%，而实验室人均产出提高了7%，并且大摩预计未来 仍有充足空间可进一步大幅提升。 智通财经APP获悉，华尔街大行摩根士丹利近日发布研报称，规模较大的独立医学实验室(ICL)竞争护 城河持续扩大，主要得益于其率先应用人工智能并强化高端检验能力，摩根士丹利分析团队预计ICL行 业面临的一些挑战因素未来将会逐步被消化。鉴于艾迪康控股(09860)坐拥高于同行的业绩增长数据以 及更加健康的资产负债表，摩根士丹利分析团队重申对艾迪康控股(09860)股票的"增持"评级，并且予 以10港元目标价。 摩根士丹利分析团队表示，由于业务性质，ICL处于人工智能/数字化应用的最前沿领域，领先企业的竞 争优势持续扩大： ICL业务本身具有劳动/资本密集型的特性，且业务正式经营过程中产生的大量数据 使其位居中国医疗领域人工智能应用的前沿。 与此同时，大摩表示，常规临床检验在短期内可能仍然将面临政策驱动的价格/检验量压力，基础效应 可能将在2025年底至2026年初逐步消化，这与上游IVD ...

Core Insights - Aidi Kang Holdings (艾迪康控股) has announced the full acquisition of Yuande Youqin and Yuande Weikang, marking a strategic expansion in the blood testing sector with a total consideration of 50 million RMB in cash and 4% of the company's common stock [1][4] - The acquisition aims to enhance Aidi Kang's capabilities in high-end specialty testing, particularly in the blood disease diagnosis field, leveraging the expertise of Yuande Youqin and Yuande Weikang [1][5] Group 1: Business Expansion and Market Position - Aidi Kang is focusing on the specialty testing (特检) sector, which has become a core growth engine, with a projected revenue growth of over 18% year-on-year in 2024, particularly in tumor detection, which has seen a 47% increase [2][3] - The global blood testing market is expected to grow from approximately $90.6 billion in 2024 to $126.1 billion by 2029, with a compound annual growth rate (CAGR) of 6.88%, and the Chinese market is projected to reach 100 billion RMB by 2025 [3][4] Group 2: Strategic Acquisition Details - Yuande Youqin is recognized as a leading enterprise in blood disease diagnostics, providing over 200,000 testing services annually and covering more than 400 tertiary hospitals [5][6] - The acquisition will significantly enhance Aidi Kang's product line in blood testing, providing a comprehensive solution that includes both routine and high-end specialty tests, thereby improving clinical service capabilities [8][9] Group 3: Future Growth and Innovation - The partnership is expected to create a synergistic effect, enhancing Aidi Kang's market presence and driving the development of a "testing-reagents-clinical" integrated ecosystem [9] - The collaboration will leverage Yuande Youqin's extensive sample resource library and Aidi Kang's AI diagnostic technology to establish a closed-loop innovation system, promoting standardization and intelligence in the industry [8][9]

Group 1 - Aidi Kang Holdings has signed a full acquisition of Suzhou Yuande Youqin Medical Laboratory Co., Ltd. and Suzhou Yuande Weikang Biomedicine Co., Ltd., marking a strategic move in the precision diagnosis of blood diseases [1] - The acquisition aims to strengthen Aidi Kang's technical barriers and market leadership in the high-end specialty testing field [1][4] - The signing ceremony was attended by key officials and executives, indicating the significance of this acquisition within the industry [1] Group 2 - Yuande Youqin has rapidly developed since its establishment in 2017, creating a comprehensive MICM precision diagnosis platform for hematological tumors, covering various blood system diseases [3] - The laboratory has received multiple authoritative certifications, demonstrating its strong management capabilities and compliance with international standards [3] - Yuande Youqin provides over 200,000 testing services annually, serving more than 400 tertiary hospitals with over 300 testing items [3] Group 3 - Yuande Weikang, established in 2014, specializes in flow cytometry detection and has developed various testing kits for blood diseases, with multiple GMP-standard workshops [3] - The company focuses on providing professional and standardized blood disease detection solutions, enhancing its research and development capabilities [3] Group 4 - Aidi Kang aims to integrate high-quality resources through this acquisition to expand service capabilities and deepen professional advantages [4] - The acquisition of Yuande Youqin will enhance Aidi Kang's expertise in high-value ICL projects, while the acquisition of Yuande Weikang will extend its capabilities in diagnostic reagent research and production [4] - This strategic integration is expected to improve Aidi Kang's innovation and operational efficiency, further solidifying its leading position in the industry [4]